Some of the world’s most powerful pharmaceutical companies backed down on planned price increases following a new transparency law in California and social media hectoring from President Donald Trump.
Congress has finally passed the Right to Try Act, but does it go far enough?
The government agency released its latest guidance this week.
11 questions for the GW CEO on the watershed moment.
The Office of Prescription Drug Promotion has sent its second warning letter of the year.
Across the political spectrum, most Americans favor President Donald Trump’s proposal to show drug prices in advertisements.
The approval answers one question but raises others.
It’s still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what’s included in FDA labeling.
For the first time, the nonprofit is trying to eliminate bans on gay and bisexual men donating blood in countries other than the U.S.
Please login or register first to view this content.
